Aronora
Clinical-stage biopharmaceutical company focused on development and commercialization of biologic therapies for blood and thrombotic disorders. The organization advances recombinant antibodies, engineered protein therapeutics, and antisense oligonucleotides from discovery through IND-enabling studies and clinical trials, and has engaged in partnerships for development and manufacturing.
Industries
Nr. of Employees
small (1-50)
Products
AB002 (protein C activator enzyme)
Engineered protein C activator designed to increase local activated protein C concentration at thrombus sites to interrupt thrombus development while preserving hemostasis.
AB023 (factor XI contact activation inhibitor)
Recombinant antibody that selectively inhibits factor XI activation via contact (factor XII-mediated) pathways to provide antithrombotic effect with a potentially reduced bleeding profile.
AB054 (factor XII inhibitor)
Recombinant antibody targeting factor XII to inhibit FXII-dependent thrombin generation and kallikrein-mediated inflammatory pathways; in IND-enabling development.
AB062 (antisense oligonucleotide targeting thrombopoietin)
Antisense oligonucleotide designed to reduce hepatic thrombopoietin synthesis as a modality to modulate platelet counts.
Osocimab (factor XIa antibody, co-developed)
Fully human monoclonal antibody targeting factor XIa being developed under a collaboration with an industry partner for prevention of thromboembolism.
AB002 (protein C activator enzyme)
Engineered protein C activator designed to increase local activated protein C concentration at thrombus sites to interrupt thrombus development while preserving hemostasis.
AB023 (factor XI contact activation inhibitor)
Recombinant antibody that selectively inhibits factor XI activation via contact (factor XII-mediated) pathways to provide antithrombotic effect with a potentially reduced bleeding profile.
AB054 (factor XII inhibitor)
Recombinant antibody targeting factor XII to inhibit FXII-dependent thrombin generation and kallikrein-mediated inflammatory pathways; in IND-enabling development.
AB062 (antisense oligonucleotide targeting thrombopoietin)
Antisense oligonucleotide designed to reduce hepatic thrombopoietin synthesis as a modality to modulate platelet counts.
Osocimab (factor XIa antibody, co-developed)
Fully human monoclonal antibody targeting factor XIa being developed under a collaboration with an industry partner for prevention of thromboembolism.
Expertise Areas
- Clinical trial management
- Biologic therapeutic development
- Antithrombotic and coagulation biology
- Preclinical translational research
Key Technologies
- Recombinant monoclonal antibody therapeutics
- Antisense oligonucleotide therapeutics
- Protein engineering (engineered thrombin/protein C activators)
- In vivo animal models (rodent and nonhuman primates)